Hawaii may soon be more than just Paradise. It may also be a psychedelic therapy hub. A new state measure aims to legalize psilocybin, the hallucinogenic compound in certain mushrooms. The new bill was introduced by democratic Senators Stanley Chang, Laura Clint Acasio, Les Ihara Jr., and Maile Shimabukuro. If approved, Hawaii’s Department of Health would establish “designated treatment centers for the therapeutic administration of psilocybin and psilocyn.” The legislation would also remove the substances from the state’s list of Schedule 1 controlled substances. The proposed measure comes less than a year after the Aloha State saw legislation introduced to approve the study of psychedelic mushrooms. There are currently dozens of studies underway across the globe looking at psilocybin as a viable treatment option for a range of mental health issues. In particular, psilocybin is showing potential in treating patients diagnosed with treatment-resistant depression. If passed, the measure would also see the creation of a seven-person review panel aimed at assessing the policy change. The move comes on the heels of similar announcements by California and Florida legislators. Last November, voters in the nation’s capital and in Oregon decriminalized psychedelics. Oregon also became the first state to legalize psilocybin therapy. It now will develop standards for certifying therapists and treatment. Read more at: https://psychedelicspotlight.com/hawa… **Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing.
Similar Posts
MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀
In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥
MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.
MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.
Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMedStock #MindMed #MMED #MMEDF
Dr. Matthew Johnson discusses Psychedelics, the Hard Problem of Consciousness and UFOs
During our time in Wonderland Miami, we had the pleasure to meet and interview Dr. Matthew Johnson of Johns Hopkins University. In this Psychedelic Spotlight Interview, we discuss a wide range of topics surrounding psychedelics and their effectiveness as treatments for ailments like tobacco addiction and PTSD. Of course, our conversation took as spin as we also touched on topics such as UFOs, DMT experiences and the CIA!
Timestamps:
0:00 – Intro
1:10 – Dr. Johnson’s latest updates on treating smoking cessation with psilocybin
6:55 – MAPS’ study using MDMA to treat PTSD
7:20 – DMT’S mystical experiences of perceiving aliens, machine elves and autonomous beings
13:08 – CIA research on psychedelics for telepathy and remote viewing
15:01 – What is consciousness?
19:02 – The intriguing evidence of UFOs?
21:40 – Where do we see psychedelics going in the next 5 years?
Make sure to like, share and subscribe if you enjoyed this episode!
#Psychedelics #MatthewJohnson #UFO
Discussing Extraction and the Colorado Gray Market with Nick Gay
In this episode, Dennis Walker sits down with Nick Gay, the Head of Product Development at Ousia Labs, to talk about what extraction is and why it has become a focus of many entrepreneurs in the psychedelic space, as well as discussing the massive gray market that is developing in Colorado.
Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)
In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.
Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.
Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:
MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%
The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.
#psychedelicstocks #shroomstocks #mindmedstock
https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Is Ketamine Therapy an Effective Treatment for Alcohol Use Disorder? A New Phase 2 Study Says YES!
Is ketamine therapy an effective treatment for alcohol use disorder?…
BIG Updates On MindMed, Compass, NUMI, TRYP, TRUFF, LOBE & More Plus Clinical Trial Progress
Hey psychedelic investors, this week we have Big Updates on MindMed, Compass, NUMI TRYP, TRUFF, ATAI, SHRM and LOBE Sciences and some amazing Ayahuasca study results which are detrimental to DMT research and this molecule potential effects on depression and anxiety.
Timestamps:
0:00 – Intro
0:52- Effects of DMT, taken using the ayahuasca drink, on depression and anxiety
5:26 – MindMed ( MMED / MNMD / MMQ ) stared trading on NASDAQ
6:01 – MindMed finishes phase2a trials for Project LUCY
8:15 – Atai Life Sciences To IPO soon on the Nasdaq and plans to raise $100 million
9:17 – Compass Pathways ( CMPS) to raise $144 million dollars
10:35 – Numinus Wellness ( NUMI ) to begin phase 1 trial for naturally extracted psilocybin in their lab
12:15 TRYP Therapeutics (TRYP) to begin 2 phase 2a trials in 2021
13:50 – Champignon Brands (SHRM) to restart trading in Canada
14:31 – Lobe Sciences (LOBE) & Core one Labs ( CLABF) to create a Joint Venture
15:34 – Red Light Holland (TRUFF) has increased its points of sale by 144% and TRUFF and Halo Collective create Red Light Oregn, INC
Link to Numinus (NUMI) press release: https://www.newswire.ca/news-releases/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab-879795202.html?fbclid=IwAR1SmpbsTmXLs-mEy3vsUtAGKKk_xpf3FxJB3n2C-55zGJjiF0naXRetoUs
Link to Compass Pathways (CMPS) : https://www.globenewswire.com/news-release/2021/04/27/2218191/0/en/COMPASS-Pathways-launches-proposed-public-offering.html https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Link To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Link to MindMed clinical trial: https://clinicaltrials.gov/ct2/show/NCT03153579?term=lsd+anxiety&draw=2&rank=1
Link to Red LIght Holland (TRUFF) : https://www.newsfilecorp.com/release/81879/Red-Light-Holland-and-Halo-Collective-Create-Red-Light-Oregon-Inc.-Forwarding-Intentions-to-Enter-Oregon-Medicinal-Psychedelic-Market
https://www.cnbc.com/2021/04/21/atai-ipo-peter-thiel-backed-psychedelics-firm-to-raise-100-million.html
Link to Champignon Brands (SHRM) : https://www.prnewswire.com/news-releases/champignon-brands-announces-revocation-of-cease-trade-orders-301275526.html
Link to DMT study: https://www.sciencedirect.com/science/article/pii/S2666915321000251?fbclid=IwAR1-0HC9fxkL2Z47TEubMGsrqKInj61xLvBK4OW_C3FEQgv5VomoCSoNeQo
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #numiStock